Q4 2025 10X Genomics Inc Earnings Call Transcript
Key Points
- 10x Genomics Inc (TXG) exceeded its revenue guidance for Q4 2025, achieving $166 million in revenue.
- The company reported double-digit growth in single-cell consumables volumes each quarter, driven by new products like FLEX and on-chip multiplexing.
- Spatial consumables revenue saw double-digit growth for the year, with strong demand for the Xenium platform.
- 10x Genomics Inc (TXG) launched several new products, including the Flex Apex assay and enhancements to its spatial platforms, expanding its capabilities.
- The company strengthened its balance sheet, increasing its cash balance by over $100 million year-over-year, reflecting disciplined cost management.
- Customer spending remained subdued, with capital equipment purchases particularly constrained due to uncertain research funding dynamics.
- Total instrument revenue declined by 36% in Q4 2025, with significant drops in both Chromium and spatial instrument revenues.
- The Americas region experienced a 6% revenue decline, attributed to continued softness in the US academic and government funding environment.
- Visium, one of the company's spatial platforms, did not grow in 2025, with all spatial consumables growth driven by Xenium.
- The company anticipates continued pressure on CapEx funding, which will likely impact instrument revenue in 2026.
Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics fourth-quarter and full year 2025 earnings call. (Operator Instructions)
I would now like to turn the call over to Cassie Corneau, Senior Director, Investor Relations and Strategic Finance. Please go ahead.
Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the fourth quarter and full year ended December 31, 2025. If you have not received this news release or would like to be added to the companyâs distribution list, please send an email to [email protected]. An archived webcast of this call will be available on the Investor tab of the companyâs website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, Iâd like to remind you that management will make statements during this call that are forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
